Browse EX-10 agreements

Exhibit 10.7

ENERGY VAULT HOLDINGS, INC.
2022 EQUITY INCENTIVE PLAN
NOTICE OF STOCK OPTION GRANT

You have been granted the following option to purchase shares of the Common Stock of Energy Vault Holdings, Inc. (the “Company”) on the terms and conditions set out below:

Name of Optionee:    [______]

Total Number of Shares:    [______]

Type of Option (U.S. Tax Status):    [Incentive Stock Option][Nonstatutory Stock Option]

Exercise Price per Share:    [______]

Date of Grant:    [______]

Vesting Commencement Date:    [______]

Vesting Schedule:    [To be specified in the individual award agreements]

Expiration Date:    [______]. This option expires earlier if your Service terminates earlier, as described in the Stock Option Agreement, and may terminate earlier in connection with certain corporate transactions as described in Article 9 of the Plan.

You and the Company agree that this option is granted under and governed by the terms and conditions of the Company’s 2022 Equity Incentive Plan, as the same may be amended from time to time (the “Plan”) and the Stock Option Agreement (including, if applicable, the Appendix for Non-U.S. Participants), both of which are attached to, and made a part of, this document. Capitalized terms not otherwise defined herein shall have the meanings assigned to such terms in the Plan.

…

July 13, 2026

Nitin Dahiya

48 Bedford Road

Summit, NJ 07901

n2dahiya@gmail.com

Re:Offer and Terms of Employment

Dear Nitin,

It gives me great pleasure to offer you the position of Chief Financial Officer for Energy Vault Holdings, Inc. (the “Company”). If you accept this offer, the terms and conditions of this offer letter agreement (the “Agreement”), in addition to the attachments enclosed with this Agreement, will apply to your at-will employment with the Company:

1.Start Date and Duties. If you accept this offer, and contingent on the other conditions set forth herein, your first day of employment will be 27 July, 2026. You will report to Robert A. Piconi, Chairman, Co-Founder & Chief Executive Officer. You shall perform duties consistent with your position in a professional and competent manner, and throughout your employment with the Company devote your time to such matters as the Company may reasonably require. You shall use your best efforts to complete all assignments and adhere to the Company’s procedures and policies in effect.

2.Compensation. Your gross annual base salary will be $435,000 USD, subject to standard withholdings and authorized deductions (“Base Salary”), and payable on a bi-weekly basis in accordance with the Company’s normal payroll practices. By virtue of your duties, responsibilities, and compensation, your role is an exempt position, meaning you are not eligible for overtime compensation. Your salary is subject to modification during your employment in accordance with the Company’s practices, policies, or procedures.

…

CALISTOGA RESILIENCY CENTER, LLC

4360 Park Terrace Drive, Suite 100
Westlake Village, CA 91361

					New York, New York August 4, 2025
Re:    Amendment No. 1 to the Note Purchase Agreement
TO EACH OF THE NOTEHOLDERS NAMED ON THE SIGNATURE PAGES HEREOF

Ladies and Gentlemen:

…

DMS_US.374368937.12 124054739.9 LEASE AGREEMENT BETWEEN 184 PROPERTY OWNER, LLC, a New Jersey limited liability company, LANDLORD, -AND- AQUESTIVE THERAPEUTICS, INC., a Delaware corporation, TENANT DATED: , 2026

---

TABLE OF CONTENTS Page -i- ARTICLE 1 DEFINITIONS ................................................................................................. 4 ARTICLE 2 DEMISE, TERM.............................................................................................. 5 ARTICLE 3 BASIC RENT; ADDITIONAL RENT ............................................................ 6 ARTICLE 4 REAL ESTATE TAXES ................................................................................. 7 ARTICLE 5 OPERATING EXPENSES ............................................................................ 10 ARTICLE 6 ELECTRICITY .............................................................................................. 12 ARTICLE 7 MAINTENANCE; ALTERATIONS; REMOVAL OF TRADE FIXTURES .................................................................................................... 13 ARTICLE 8 USE OF PREMISES ...................................................................................... 15 ARTICLE 9 LANDLORD’S SERVICES .......................................................................... 16 ARTICLE 10 COMPLIANCE WITH REQUIREMENTS .................................................. 20 ARTICLE 11 COMPLIANCE WITH ENVIRONMENTAL LAWS .................................. 21 ARTICLE 12 DISCHARGE OF LIENS

…

THE SYMBOL “[****]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. LICENSE AND SUPPLY SECOND AMENDMENT This LICENSE AND SUPPLY SECOND AMENDMENT (“Second Amendment”) is entered into as of 20 April 2026 (the “Second Amendment Effective Date”) by and between Aquestive Therapeutics, Inc., a Delaware corporation having its principal place of business at 30 Technology Drive, Warren, New Jersey 07059 (“Aquestive”), and Atnahs Pharma UK Limited, a company registered in England and Wales having its principal place of business at Sovereign House, Miles Gray Road, Basildon, Essex SS14 3FR (“Pharmanovia”). Aquestive and Pharmanovia are sometimes referred to hereinafter individually as a “Party” and collectively as the “Parties.” RECITALS: A. Aquestive and Pharmanovia entered into a License and Supply Agreement related to the Product in certain territories as specified therein on September 26, 2022, which was subsequently amended by an Amendment Agreement dated 27 March 2023 (together, the “Agreement”). B. Aquestive and Pharmanovia have agreed to enter into this Second Amendment in order to further amend certain terms of the Agreement. C. In consideration of the foregoing and the mutual representations, warranties and covenants contained herein, the Parties, intending to be legally bound hereby, agree as follows: 1. DEFINITIONS Unless otherwise defined in this Second Amendment, capitalized terms used in this Amendment have

…

SEPARATION AND GENERAL RELEASE AGREEMENT

This SEPARATION AND GENERAL RELEASE AGREEMENT (this “Agreement”) is entered into by and between Comscore, Inc., a Delaware corporation (the “Company”), and Steve Bagdasarian (“Executive”). The Company and Executive are each referred to herein individually as a “Party” and collectively as the “Parties.”

WHEREAS, Executive and the Company are parties to that certain Severance Agreement effective as of March 27, 2024 (the “Severance Agreement”);

WHEREAS, Executive and the Company have agreed that Executive’s employment with the Company will end on December 1, 2026, unless terminated earlier due to a termination by the Company for Cause (as defined in the Severance Agreement) or due to Executive’s resignation (the date that Executive’s employment with the Company ends, the “Separation Date”);

WHEREAS, the Company seeks to retain Executive prior to the Separation Date for the purpose of obtaining Executive’s assistance in transitioning his duties, and Executive wishes to provide such assistance;

WHEREAS, subject to the terms of this Agreement, the Parties wish for Executive to be eligible to receive certain severance payments and other benefits, which payments and benefits are conditioned upon Executive’s satisfaction of the terms of this Agreement; and

WHEREAS, the Parties wish to resolve any and all claims that Executive has or may have against the Company and any of the other Released Parties (as defined below), including any claims that Executive may have arising out of Executive’s employment or the end of such employment.

…

COMSCORE, INC.

CHANGE OF CONTROL AND SEVERANCE AGREEMENT

This Change of Control and Severance Agreement (the “Agreement”) is made and entered into by and between Mary Margaret Curry (“Executive”) and comScore, Inc., a Delaware corporation (the “Company”), effective as of the date on which this Agreement has been executed by all parties hereto (the “Effective Date”).

RECITALS

1.The Compensation Committee (the “Committee”) of the Board of Directors of the Company (the “Board”) believes that it is in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication and objectivity of Executive, to provide Executive with an incentive to continue his or her employment, and to motivate Executive to maximize the value of the Company for the benefit of its stockholders.

2.The Committee believes that it is imperative to provide Executive with certain severance benefits upon Executive’s termination of employment under certain circumstances. These benefits will provide Executive with enhanced financial security and incentive and encouragement to remain with the Company.

3.The Company and Executive desire to terminate the Change of Control Agreement, dated July 6, 2022, and the Severance Agreement, dated July 6, 2022, between the Company and Executive (collectively, the “Prior Agreements”) in exchange for each party’s entry into this Agreement.

4.Certain capitalized terms used in the Agreement are defined in Section 6below.

AGREEMENT

…

August 9, 2026

By E-mail

Mary Margaret Curry

Comscore, Inc.

11950 Democracy Drive

Suite 600

Reston, VA 20190

Dear Mary Margaret:

I am pleased to inform you that the Board of Directors (the “Board”) of Comscore, Inc. (the “Company”) has approved your eligibility for new equity incentive awards under the Company’s 2018 Equity and Incentive Compensation Plan (the “Plan”), subject to your agreement to the terms set forth in this letter (this “Agreement”).

Upon execution of this Agreement by you and the Company, the letter agreement, dated July 5, 2022, between you and the Company (the “2022 Letter”) will be deemed amended to reflect the following terms, which will govern your continued employment with the Company.

1.Equity Awards. As soon as practicable (and subject to terms approved by the Board and set forth in the applicable award agreement), you will receive (a) a one-time grant of options to purchase 60,000 shares of Comscore common stock under (and pursuant to the terms of) the Plan, with a per share exercise price equal to the closing price per share of Comscore common stock on the date of grant, which grant will vest in equal annual installments over four years subject to your continued service with the Company through each vesting date; and (b) a one-time grant of 60,000 restricted stock units under (and pursuant to the terms of) the Plan, which grant will vest in equal annual installments over four years subject to your continued service with the Company through each vesting date, with settlement deferred until the earlier of a separation from service or a

…

August 10, 2026

By E-mail

Matt McLaughlin

Comscore, Inc.

11950 Democracy Drive

Suite 600

Reston, VA 20190

Dear Matt:

This letter (this “Agreement”) modifies the letter agreement, dated May 28, 2026, between you and the Company (the “CEO Letter”). Upon execution of this Agreement by you and the Company, the CEO Letter will be deemed amended to reflect the following terms, which will govern your continued employment with the Company.

1.Base Salary Reduction. Effective October 1, 2026, your base salary will be reduced by 20% such that, as of such date, your annualized base salary will be $500,000 for the remainder of 2026 and $515,000 for 2027. Your base salary will continue to be paid semi-monthly (on the 15thand last day of each month) in accordance with Comscore’s standard payroll practices and subject to applicable payroll deductions and withholdings. By signing this Agreement, you are agreeing to this salary reduction and are waiving any notice period that may be required by your state of residence and/or employment. Your annualized base salary will revert to no less than $663,063 (your current salary plus annual escalators per the CEO Letter) effective January 1, 2028.

…

Achieve Life Sciences, Inc.

Employment Agreement

This Employment Agreement (this “Agreement”) is entered into by and between Andrew D. Goldberg, MD (the “Executive”) and Achieve Life Sciences, Inc., a Delaware corporation (the “Employer” or the “Company”) as of April 16, 2026 (the “Effective Date”). The terms of the Executive’s employment with the Company (“Employment” and commencement thereof, the “Start Date”) are set forth in this Agreement. Defined terms used in this Agreement, and not defined in line, are set forth in Section 7.

1.

Duties and Scope of Employment.

The Employer agrees to employ the Executive in the position of Chief Executive Officer (“CEO”), reporting directly to the Company’s Board of Directors (the “Board”). The Executive shall have such duties, authority and responsibilities that are commensurate with the position of CEO.

The Executive will be appointed to the Board effective on or before the Start Date, and for so long as Executive serves as the CEO, subject to the requirements of applicable law (including, without limitation, any rules or regulations of any exchange on which the common stock of the Company is listed), the Board and/or a committee of the Board will nominate Executive for re-election to the Board at each annual meeting at which Executive is subject to re-election. If Executive’s position as CEO is terminated by Executive or the Company for any reason, Executive agrees to promptly resign from the Board and any committee thereof, unless requested otherwise by the Board (the “Resignation Requirement”).

…

DATED 08 May 2026

(1) ACHIEVE PHARMA UK LIMITED

(2) ACHIEVE LIFE SCIENCES, INC.

(3) RICHARD STEWART

SETTLEMENT AGREEMENT

WITHOUT PREJUDICE AND SUBJECT TO CONTRACT

---

THISAGREEMENTis made on 08 May 2026

BETWEEN:-

(1) ACHIEVE PHARMA UK LIMITED(company number 06751116) whose registered office is at 10 Station Road, Henley-On-Thames, Oxfordshire, RG9 1AY (the "Company");

(2) ACHIEVE LIFE SCIENCES, INC.whose registered office is at 22722 29th Dr. SE Suite 100, Bothell, WA, 98021 (the "Achieve Inc."); and

(3) RICHARD STEWARTof (the "Executive").

WHEREAS:-

(A)

The Executive is employed by the Company as Chairman and Chief Executive Officer of the Company and Chief Executive Officer of Achieve Inc. pursuant to a contract between the Executive and the Company dated 9 May 2025 as amended or varied from time to time (the "Service Agreement").

(B)

Pursuant to the terms of this Agreement, the parties have agreed that the Executive's employment by the Company and appointment as Chairman and Chief Executive Officer of the Company will terminate on the date of this Agreement (the "Termination Date"). The Executive's directorship of the Company shall end on the Termination Date. The Executive’s appointment as Chief Executive Officer of Achieve Inc., terminated on 17 April 2026.

(C)

…

August 5, 2026

David Rodman, M.D.

Re:    Amendment to Employment Letter Agreement

Dear Dr. Rodman:

This is an amendment (this “Amendment”) to the existing amended and restated employment letter agreement dated February 1, 2023 (the “Letter Agreement”), between you and Mineralys Therapeutics, Inc. (the “Company”). The Company is amending the Letter Agreement to provide that, effective asof August 10, 2026, you shall continue your employment with the Company in a non-executive capacity as a Strategic Advisor and shall perform such duties as are customarily associated with such position and such other duties as are assigned to you by your supervisor, the Company’s Chief Executive Officer. Your job duties and responsibilities may change from time to time, without advance notice, in the sole discretion of the Company. Your employment with the Company will continue to be “at-will” at all times.

Except as specifically set forth in this Amendment, all of the remaining terms of the Letter Agreement shall remain unchanged and in full force and effect. For the avoidance of doubt, you acknowledge and agree that you consent and agree to the terms and conditions of this Amendment, and that nothing contained herein shall constitute, give rise to or be deemed to constitute or give rise to Good Reason for purposes of the Letter Agreement or any other compensatory agreement to which you are a party with the Company.

…